EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Targeted small molecule therapy and inhibitors for lymphoma

Zhong-Hui Wang, Xiang Zheng, Guo-Wu Rao iD, Quan Zheng

Future Medicinal Chemistry · 2024

DOI: 10.1080/17568919.2024.2359893 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Medicinal Chemistry, 2024. Verfasst von Zhong-Hui Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, P. R. China. Hauptthemen laut MEDLINE: Lymphoma, Antineoplastic Agents, Agammaglobulinaemia Tyrosine Kinase, Small Molecule Libraries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: New-shoot Talents Program of Zhejiang Province, Science and Technology Program of Zhejiang Province (Key Innovative Team), National Undergraduate Training Program for Innovation and Entrepreneurship of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymphoma, a blood tumor, has become the ninth most common cancer in the world in 2020. Targeted inhibition is one of the important treatments for lymphoma. At present, there are many kinds of targeted drugs for the treatment of lymphoma. Studies have shown that Histone deacetylase, Bruton's tyrosine kinase and phosphoinositide 3-kinase all play an important role in the occurrence and development of tumors and become important and promising inhibitory targets. This article mainly expounds the important role of these target protein in tumors, and introduces the mechanism of action, structure-activity relationship and clinical research of listed small molecule inhibitors of these targets, hoping to provide new ideas for the treatment of lymphoma. [Box: see text].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphomaAntineoplastic AgentsAgammaglobulinaemia Tyrosine KinaseSmall Molecule LibrariesHumansHistone DeacetylasesProtein Kinase InhibitorsHistone Deacetylase InhibitorsStructure-Activity RelationshipPhosphoinositide-3 Kinase InhibitorsMolecular Targeted Therapy

Stichwörter der Autor:innen

BTKHDACPI3K δinhibitorlymphomatreatmenttumor

Substanzen

Antineoplastic AgentsAgammaglobulinaemia Tyrosine KinaseSmall Molecule LibrariesHistone DeacetylasesProtein Kinase InhibitorsHistone Deacetylase InhibitorsPhosphoinositide-3 Kinase Inhibitors

Autor:innen und Institutionen

  • College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, P. R. China.
  • Core Facility,The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou 324000, P. R. China.

ORCID-Profile: Guo-Wu Rao

Förderung

  • New-shoot Talents Program of Zhejiang Province
  • Science and Technology Program of Zhejiang Province (Key Innovative Team)
  • National Undergraduate Training Program for Innovation and Entrepreneurship of China

Zitieren

APA

Wang, Z. H., Zheng, X., Rao, G. W., & Zheng, Q. (2024). Targeted small molecule therapy and inhibitors for lymphoma. Future Medicinal Chemistry. https://doi.org/10.1080/17568919.2024.2359893

Vancouver

Wang ZH, Zheng X, Rao GW, Zheng Q. Targeted small molecule therapy and inhibitors for lymphoma. Future Medicinal Chemistry. 2024. doi:10.1080/17568919.2024.2359893

BibTeX
@article{Wang2024,
  author = {Wang, Zhong-Hui and Zheng, Xiang and Rao, Guo-Wu and Zheng, Quan},
  title = {Targeted small molecule therapy and inhibitors for lymphoma},
  journal = {Future Medicinal Chemistry},
  year = {2024},
  doi = {10.1080/17568919.2024.2359893}
}
Kostenlos starten →